180 related articles for article (PubMed ID: 8922249)
1. Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group.
Schellong G
Baillieres Clin Haematol; 1996 Sep; 9(3):619-34. PubMed ID: 8922249
[TBL] [Abstract][Full Text] [Related]
2. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G
Ann Oncol; 1996; 7 Suppl 4():67-72. PubMed ID: 8836413
[TBL] [Abstract][Full Text] [Related]
3. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Hodgkin's disease: treatment in the late 1990s.
Schellong G
Ann Oncol; 1998; 9 Suppl 5():S115-9. PubMed ID: 9926249
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group.
Schellong G; Brämswig JH; Hörnig-Franz I; Schwarze EW; Pötter R; Wannenmacher M
Ann Oncol; 1994; 5 Suppl 2():113-5. PubMed ID: 8204510
[TBL] [Abstract][Full Text] [Related]
6. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.
Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L
Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937
[TBL] [Abstract][Full Text] [Related]
8. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
[TBL] [Abstract][Full Text] [Related]
9. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
10. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
[TBL] [Abstract][Full Text] [Related]
11. An approach to reduce treatment and invasive staging in childhood Hodgkin's disease: the sequence of the German DAL multicenter studies.
Schellong G; Brämswig JH; Schwarze EW; Wannenmacher M
Bull Cancer; 1988; 75(1):41-51. PubMed ID: 3282575
[TBL] [Abstract][Full Text] [Related]
12. [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82].
Schellong G; Brämswig J; Ludwig R; Gerein V; Jobke A; Jürgens H; Kabisch H; Stollmann B; Weinel P; Gadner H
Klin Padiatr; 1986; 198(3):137-46. PubMed ID: 3523020
[TBL] [Abstract][Full Text] [Related]
13. Treatment of children with Hodgkin's disease--results of the German Pediatric Oncology Group.
Schellong G; Brämswig JH; Hörnig-Franz I
Ann Oncol; 1992 Sep; 3 Suppl 4():73-6. PubMed ID: 1450084
[TBL] [Abstract][Full Text] [Related]
14. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90.
Dieckmann K; Pötter R; Wagner W; Prott FJ; Hörnig-Franz I; Rath B; Schellong G
Radiother Oncol; 2002 Feb; 62(2):191-200. PubMed ID: 11937246
[TBL] [Abstract][Full Text] [Related]
15. Risk adapted combined modality treatment in children with Hodgkin's disease: NCI, Cairo.
El-Badawy S; Aboulnaga S; Abou Gabal A; Mokhless A; Zamzam M; Sidhom I; Ebeid E; Hussein H
J Egypt Natl Canc Inst; 2008 Jun; 20(2):99-110. PubMed ID: 20029465
[TBL] [Abstract][Full Text] [Related]
16. [Significance of procarbazine in the chemotherapy of Hodgkin's disease--a report of the Cooperative Therapy Study DAL-HD-85].
Schellong G; Hörnig I; Brämswig J; Bökkerink JP; Steinhoff A; Ludwig R; Niethammer D; Reiter A; von Lengerke HJ; Heinecke H
Klin Padiatr; 1988; 200(3):205-13. PubMed ID: 3062257
[TBL] [Abstract][Full Text] [Related]
17. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
[TBL] [Abstract][Full Text] [Related]
18. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
19. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
Diehl V; Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Wilmanns W; Kirchner H; Schoppe W; Petsch S
Med Oncol Tumor Pharmacother; 1989; 6(2):155-62. PubMed ID: 2473363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
